Free Trial

Dare Bioscience (DARE) Competitors

Dare Bioscience logo
$2.11 +0.02 (+0.96%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$2.12 +0.01 (+0.47%)
As of 10/24/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DARE vs. LFVN, SLGL, EXOZ, MGX, MGNX, HLVX, ATYR, SCLX, CNTB, and VIRI

Should you be buying Dare Bioscience stock or one of its competitors? The main competitors of Dare Bioscience include Lifevantage (LFVN), Sol-Gel Technologies (SLGL), eXoZymes (EXOZ), Metagenomi (MGX), MacroGenics (MGNX), HilleVax (HLVX), aTyr Pharma (ATYR), Scilex (SCLX), Connect Biopharma (CNTB), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry.

Dare Bioscience vs. Its Competitors

Lifevantage (NASDAQ:LFVN) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

In the previous week, Lifevantage and Lifevantage both had 2 articles in the media. Lifevantage's average media sentiment score of 0.95 equaled Dare Bioscience'saverage media sentiment score.

Company Overall Sentiment
Lifevantage Positive
Dare Bioscience Positive

Lifevantage has higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifevantage$228.53M0.48$9.81M$0.7411.72
Dare Bioscience-$17.70K-1,606.85-$4.05M-$2.14-0.99

Lifevantage currently has a consensus price target of $30.50, indicating a potential upside of 251.79%. Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 373.93%. Given Dare Bioscience's higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Lifevantage.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifevantage
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Dare Bioscience
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

35.3% of Lifevantage shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 22.0% of Lifevantage shares are held by company insiders. Comparatively, 4.8% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lifevantage has a net margin of 4.29% compared to Dare Bioscience's net margin of 0.00%. Lifevantage's return on equity of 33.75% beat Dare Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifevantage4.29% 33.75% 15.26%
Dare Bioscience N/A N/A -103.70%

Lifevantage has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Summary

Lifevantage beats Dare Bioscience on 11 of the 13 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DARE vs. The Competition

MetricDare BioscienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$28.17M$3.42B$6.24B$10.69B
Dividend YieldN/A2.27%5.72%4.82%
P/E Ratio-0.9927.6331.3430.83
Price / Sales-1,606.85461.42562.89174.99
Price / CashN/A46.1437.0861.44
Price / Book-3.0610.4012.056.61
Net Income-$4.05M-$52.83M$3.33B$277.10M
7 Day Performance3.94%2.10%1.93%2.56%
1 Month Performance1.44%12.33%7.77%3.77%
1 Year Performance-42.19%14.14%56.40%33.01%

Dare Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DARE
Dare Bioscience
2.3367 of 5 stars
$2.11
+1.0%
$10.00
+373.9%
-39.7%$28.17M-$17.70K-0.9930Analyst Forecast
LFVN
Lifevantage
4.2843 of 5 stars
$9.06
+1.1%
$30.50
+236.6%
-33.2%$113.71M$228.53M12.24260Analyst Forecast
SLGL
Sol-Gel Technologies
1.4728 of 5 stars
$39.95
+2.5%
N/A+526.0%$108.62M$11.54M-32.4850News Coverage
Positive News
Analyst Forecast
EXOZ
eXoZymes
0.3107 of 5 stars
$12.99
+0.3%
N/AN/A$108.61M$70K0.0029News Coverage
Analyst Forecast
MGX
Metagenomi
2.9907 of 5 stars
$2.85
-0.3%
$10.00
+250.9%
+50.5%$107.35M$52.29M-1.21236News Coverage
Analyst Upgrade
MGNX
MacroGenics
4.5253 of 5 stars
$1.64
-3.0%
$3.60
+119.5%
-48.9%$106.82M$149.96M-2.88430Positive News
Analyst Forecast
HLVX
HilleVax
N/A$2.09
flat
$2.00
-4.3%
N/A$104.79MN/A-1.4620
ATYR
aTyr Pharma
3.06 of 5 stars
$0.97
-8.9%
$23.25
+2,307.3%
-70.2%$103.87MN/A-1.2153Trending News
Analyst Forecast
SCLX
Scilex
2.587 of 5 stars
$14.74
-1.3%
$455.00
+2,986.8%
-47.8%$103.85M$56.59M-0.5180Positive News
Analyst Forecast
Gap Up
CNTB
Connect Biopharma
3.0492 of 5 stars
$1.82
-2.2%
$7.00
+284.6%
+39.3%$103.64M$26.03M0.00110News Coverage
Analyst Forecast
VIRI
Virios Therapeutics
N/A$5.37
-4.1%
N/A+36.1%$103.42MN/A-19.895

Related Companies and Tools


This page (NASDAQ:DARE) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners